
India’s pharmaceutical industry, a global leader in generic drug manufacturing, is bracing for potential tariff pressures from former U.S. President Donald Trump’s renewed trade rhetoric. Industry stakeholders say they have been preparing a multifaceted defense plan to safeguard exports and maintain their competitive edge in the American market.


















